| Literature DB >> 26035704 |
Xianlu Zhuo1, Jue Song2, Dairong Li3, Yongzhong Wu1, Qi Zhou4.
Abstract
MTHFR C677T polymorphism has been indicated to be a risk factor for cancers, but its association with head and neck cancer (HNC) risk remains inconclusive. In the present study, we aimed to get a more precise estimation by performing a quantitative meta-analysis. Published papers up to Jun 2014 was searched and screened. Necessary information was rigorously extracted for data pooling and analyzing, and then, subgroup analyses on ethnicity, source of controls, sample size, tumor type, smoking and drinking status were also carried out. As a result, twenty-three case-control studies including 14298 subjects were included. The overall data failed to reveal a significant association between MTHFR C677T polymorphism and HNC risk (homozygote comparison model: OR = 1.16; 95%CI = 0.93-1.45; dominant model: OR = 1.05; 95%CI = .90-1.21; recessive model: OR = 1.14; 95%CI = 0.93-1.38). However, in the subgroup analysis about drinking status, increase risk was shown in the heavy drinking subgroup (TT vs CC: OR = 3.11; 95%CI = 1.52-3.02). In conclusion, the results of the present study suggest that Homozygous TT alleles of MTHFR C677T polymorphism might be a risk factor for HNC among individuals who have a heavy drinking history. Further studies are needed to get a more definitive conclusion.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26035704 PMCID: PMC4451849 DOI: 10.1038/srep10671
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1A flow chart of the literature screening.
Characteristics of studies included in the meta-analysis.
| Weinstein | 2002 | 519 (NA/NA) | 629 (NA/NA) | Healthy controls (Age-, gender- matched; population-based) | 63.2/61.0 | Caucasian | Oral cavity | USA | 43 |
| Kureshi | 2004 | 50 (33/17) | 54 (30/24) | Healthy controls (Age-, gender- matched; population-based) | 51.3/50.2 | Mixed | Combined | Pakistan | 28 |
| Capaccio | 2005 | 65 (57/8) | 100 (88/12) | Healthy controls (Age-, gender-, drinking-, smoking status- matched; population-based) | 61.3/58.8 | Caucasian | Combined | Italy | 23 |
| Neumann | 2005 | 537 (411/126) | 545 (401/144) | Non-cancerous controls (Age-,sex-, smoking status-matched; hospital-based) | NA/NA | Caucasian | Combined | USA | 29 |
| Vairaktaris | 2006 | 110 (94/16) | 120 (102/18) | Healthy controls (Age-, sex, ethnicity-matched; population-based) | 52.1/51.5 | Caucasian | Oral cavity | GreekGerman | 41 |
| Hsiung | 2007 | 278 (193/85) | 526 (377/149) | Healthy controls (Age-, gender, town of residence-matched; population-based) | 60.1/61.0 | Mixed | Combined | USA | 26 |
| Reljic | 2007 | 81 (NA/NA) | 102 (37/65) | Healthy controls (Age-matched; population-based) | NA/NA | Caucasian | Combined | Croatia | 33 |
| Suzuki | 2007 | 237 (188/49) | 711 (564/147) | Non-cancerous controls (Age-,sex-matched; hospital-based) | 57.9/58.4 | Asian | Combined | Japan | 39 |
| Ni | 2008 | 207 (189/18) | 400 (362/38) | Healthy controls (Age-,sex-matched; population-based) | NA/NA | Asian | Larynx | China | 30 |
| Siraj | 2008 | 223 (NA/NA) | 513 (NANA) | Healthy controls (Age-matched; population-based) | NA/NA | Mixed | Thyroid | Saudi Arabia | 36 |
| Solomon | 2008 | 126 (NA/NA) | 100 (NA/NA) | Healthy individuals(population-based) | 54.7/55.4 | Asian | Oral cavity | India | 37 |
| Cao | 2010 | 529 (339/190) | 577 (367/210) | Healthy controls (Age-,sex-, ethnicity-matched; population-based) | 46.1/45.4 | Asian | Nasopharynx | China | 22 |
| Kruszyna | 2010 | 131 (131/0) | 250 (250/0) | Healthy controls (population-based) | 59.4/56.8 | Caucasian | Larynx | Poland | 27 |
| Rodrigues | 2010 | 100 (84/16) | 100 (76/24) | Non-cancerous controls (hospital-based) | 59.5/43.6 | Mixed | Combined | Brazil | 34 |
| Fard-Esfahani | 2011 | 154 (34/120) | 198 (50/148) | Non-cancerous controls (hospital-based) | NA/NA | Mixed | Thyroid | Iran | 24 |
| Prasad | 2011 | 97 (27/70) | 241 (116/125) | Healthy controls (population-based) | NA/NA | Asian | Thyroid | India | 32 |
| Sailasree | 2011 | 130 (88/42) | 139 (92/47) | Non-cancerous controls (Age-,gender-matched; hospital-based) | 58.0/57.0 | Asian | Oral cavity | India | 35 |
| Supic | 2011 | 96 (72/24) | 162 (130/32) | Non-cancerous controls(Age-, gender-, ethnicity-matched; population-based) | 58.0/58.0 | Caucasian | Oral cavity | Serbia | 38 |
| Tsai | 2011 | 620 (583/37) | 620 (572/48) | Healthy controls (Age-, gender-, habits-matched; population-based) | 65.5/63.5 | Asian | Oral cavity | China | 40 |
| Galbiatti | 2012 | 322 (280/42) | 531 (384/147) | Healthy controls (population-based) | NA/NA | Mixed | Combined | Brazil | 25 |
| Ozdemir | 2012 | 60 (11/49) | 50 (21/29) | Healthy controls (population-based) | 55.3/68.6 | Mixed | Thyroid | Turkey | 31 |
| Vylliotis | 2013 | 160 (NA/NA) | 168 (NA/NA) | Healthy controls (Age-, gender-, ethnicity-, working environment-matched; population-based) | 58.5/54.7 | Caucasian | Oral cavity | Greece | 42 |
| Kweon | 2014 | 2194 (404/1790) | 1669 (812/857) | Healthy controls (Age-, gender-, matched; population-based) | 50.6/52.2 | Asian | Thyroid | Korea | 44 |
NA: not available
Distribution of MTHFR C677T genotype among cancer cases and controls.
| Weinstein | 2002 | PCR-RFLP | 15 | 53 | 67 | 15 | 62 | 69 | 0.038 | > 0.05 |
| Kureshi | 2004 | PCR | 0 | 12 | 22 | 4 | 18 | 32 | 0.420 | > 0.05 |
| Capaccio | 2005 | PCR | 14 | 33 | 18 | 18 | 46 | 36 | 0.242 | > 0.05 |
| Neumann | 2005 | PCR | 35 | 244 | 258 | 51 | 216 | 278 | 0.914 | > 0.05 |
| Vairaktaris | 2006 | PCR-RFLP | 6 | 76 | 28 | 10 | 65 | 45 | 4.065 | < 0.05 |
| Hsiung | 2007 | PCR | 149 (a) | - | 128 | 306 (a) | - | 218 | - | - |
| Reljic | 2007 | PCR-RFLP | 9 | 27 | 45 | 8 | 59 | 35 | 6.074 | < 0.05 |
| Suzuki | 2007 | Taqman | 36 | 113 | 88 | 128 | 331 | 252 | 1.121 | > 0.05 |
| Ni | 2008 | PCR-RFLP | 64 | 95 | 48 | 61 | 187 | 152 | 0.078 | > 0.05 |
| Siraj | 2008 | PCR | 1 | 18 | 30 | 13 | 126 | 372 | 0.351 | > 0.05 |
| Solomon | 2008 | PCR-RFLP | 23 | 55 | 48 | 10 | 42 | 48 | 0.033 | > 0.05 |
| Cao | 2010 | PCR-RFLP | 32 | 169 | 310 | 30 | 188 | 334 | 0.275 | > 0.05 |
| Kruszyna | 2010 | PCR-RFLP | 10 | 52 | 69 | 20 | 104 | 126 | 0.052 | > 0.05 |
| Rodrigues | 2010 | PCR-RFLP | 13 | 43 | 44 | 14 | 40 | 46 | 1.182 | > 0.05 |
| Fard-Esfahani | 2011 | Multiplex PCR | 14 | 71 | 69 | 8 | 108 | 82 | 14.224 | < 0.05 |
| Prasad | 2011 | PCR-RFLP | 1 | 10 | 86 | 1 | 12 | 228 | 3.311 | > 0.05 |
| Sailasree | 2011 | PCR-RFLP | 1 | 8 | 92 | 1 | 29 | 108 | 0.400 | > 0.05 |
| Supic | 2011 | PCR-RFLP | 14 | 32 | 50 | 16 | 66 | 80 | 0.193 | > 0.05 |
| Tsai | 2011 | PCR-RFLP | 43 | 186 | 391 | 62 | 236 | 322 | 3.606 | > 0.05 |
| Galbiatti | 2012 | PCR-RFLP | 45 | 147 | 130 | 55 | 250 | 226 | 1.358 | > 0.05 |
| Ozdemir | 2012 | Real-time PCR | 7 | 25 | 28 | 3 | 14 | 33 | 0.781 | > 0.05 |
| Vylliotis | 2013 | PCR-RFLP | 6 | 76 | 28 | 10 | 65 | 45 | 4.065 | < 0.05 |
| Kweon | 2014 | PCR-RFLP | 422 | 1050 | 722 | 291 | 851 | 527 | 2.748 | > 0.05 |
(a): TT+CT
Main results of the pooled data in the meta-analysis
| Total | 6354/7944 | 1.16 (0.93-1.45) | 0.187 | 0.001 | 54.5% | 1.05 (0.90-1.21) | 0.540 | 0.000 | 68.7% | 1.14 (0.93-1.38) | 0.201 | 0.006 | 48.9% |
| Ethnicity | |||||||||||||
| Caucasian | 1265/1545 | 0.95 (0.72-1.26) | 0.742 | 0.860 | 0.0% | 1.05 (0.81-1.38) | 0.702 | 0.013 | 60.7% | 0.92 (0.71-1.20) | 0.533 | 0.511 | 0.0% |
| Mixed | 996/1968 | 1.41 (0.99-1.99) | 0.054 | 0.489 | 0.0% | 1.06 (0.85-1.33) | 0.597 | 0.143 | 37.5% | 1.38 (0.99-1.92) | 0.056 | 0.415 | 0.2% |
| Asian | 4093/4431 | 1.24 (0.80-1.91) | 0.331 | 0.000 | 80.3% | 1.02 (0.78-1.34) | 0.878 | 0.000 | 82.7% | 1.21 (0.86-1.70) | 0.279 | 0.001 | 73.1% |
| Source of control | |||||||||||||
| PB | 5225/6252 | 1.24 (0.94-1.63) | 0.121 | 0.001 | 59.0% | 1.10 (0.92-1.32) | 0.280 | 0.000 | 72.6% | 1.21 (0.97-1.51) | 0.086 | 0.019 | 46.4% |
| HB | 1129/1692 | 0.88 (0.66-1.17) | 0.377 | 0.392 | 2.5% | 0.92 (0.71-1.19) | 0.512 | 0.084 | 51.3% | 0.91 (0.63-1.34) | 0.646 | 0.181 | 36.1% |
| Sample size | |||||||||||||
| <500 | 1400/1881 | 1.28 (0.97-1.68) | 0.083 | 0.794 | 0.0% | 1.07 (0.83-1.38) | 0.613 | 0.001 | 62.2% | 1.24 (0.95-1.60) | 0.111 | 0.637 | 0.0% |
| ≧500 | 4954/6063 | 1.09 (0.76-1.55) | 0.641 | 0.000 | 80.6% | 1.03 (0.85-1.23) | 0.785 | 0.000 | 77.1% | 1.08 (0.80-1.45) | 0.630 | 0.000 | 76.5% |
| Smoking status | |||||||||||||
| Never-smoking | 606/919 | 0.79 (0.45-1.37) | 0.394 | 0.635 | 0.0% | 0.90 (0.71-1.14) | 0.376 | 0.605 | 0.0% | 0.81 (0.52-1.27) | 0.362 | 0.967 | 0.0% |
| Ever-smoking | 1223/1013 | 0.73 (0.49-1.10) | 0.134 | 0.018 | 82.1% | 1.24 (0.59-2.58) | 0.573 | 0.000 | 94.2% | 0.86 (0.62-1.21) | 0.392 | 0.091 | 58.3% |
| Drinking status | |||||||||||||
| Light-drinking | 201/474 | 0.78 (0.32-1.90) | 0.588 | 0.455 | 0.0% | 1.05 (0.75-1.46) | 0.795 | 0.431 | 0.0% | 0.99 (0.56-1.73) | 0.961 | 0.717 | 0.0% |
| Heavy-drinking | 409/519 | 3.11 (1.52-3.02) | 0.002 | 0.832 | 0.0% | 1.94 (0.88-4.27) | 0.099 | 0.001 | 82.1% | 1.62 (0.46-5.73) | 0.457 | 0.001 | 86.0% |
| Tumor type | |||||||||||||
| Oral cavity | 1298/1406 | 1.03 (0.66-1.61) | 0.883 | 0.099 | 43.8% | 0.99 (0.67-1.46) | 0.950 | 0.000 | 78.8% | 0.99 (0.67-1.45) | 0.939 | 0.168 | 34.0% |
| Combined | 1653/2667 | 0.97 (0.74-1.28) | 0.830 | 0.293 | 17.9% | 0.95 (0.79-1.15) | 0.613 | 0.079 | 45.0% | 0.97 (0.73-1.29) | 0.827 | 0.191 | 31.0% |
| Larynx | 338/650 | 1.82 (0.51-6.44) | 0.353 | 0.007 | 86.1% | 1.37 (0.63-3.00) | 0.432 | 0.006 | 86.8% | 1.64 (0.64-4.17) | 0.302 | 0.033 | 77.9% |
| Thyroid | 2554/2669 | 1.11 (0.92-1.32) | 0.275 | 0.416 | 0.0% | 1.28 (0.89-1.84) | 0.185 | 0.020 | 65.8% | 1.16 (0.99-1.37) | 0.063 | 0.457 | 0.0% |
| Nasopharynx | 511/552 | 1.15 (0.68-1.94) | 0.601 | — | — | 0.99 (0.78-1.27) | 0.958 | — | — | 1.16 (0.70-1.94) | 0.566 | — | — |
PB: population-based; HB: hospital-based
Heavy-drinking: >46 g ethanol/week
Figure 2Meta-analysis for the association of HNC risk with MTHFR C677T polymorphism (TT + CT versus CC; overall data).
Figure 3Publication bias test for the overall data (TT + CT versus CC). (a) Funnel plot; (b) Egger’s linear regression test.